Tyra Biosciences (TYRA) financial statements
Net income was -$120M.
Free cash flow was -$95M.
The diluted share count rose 3765% over the period (dilution).
Income statement
Fiscal years, from Tyra Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $7M | $21M | $43M | $63M | $80M | $103M |
| Selling, general and admin | $2M | $6M | $16M | $17M | $24M | $30M |
| Operating income | -$9M | -$26M | -$59M | -$80M | -$104M | -$133M |
| Income tax | $1,000 | $1,000 | $2,000 | $0 | $0 | $0 |
| Net income | -$9M | -$26M | -$55M | -$69M | -$86M | -$120M |
| EPS (diluted) | -$6.05 | -$1.91 | -$1.32 | -$1.62 | -$1.51 | -$2.01 |
| Diluted shares | 2M | 14M | 42M | 43M | 57M | 60M |
Balance sheet
Fiscal years, from Tyra Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $15M | $302M | $251M | $58M | $92M | $77M |
| Total current assets | $15M | $304M | $257M | $212M | $347M | $265M |
| Property, plant and equipment | $297,000 | $1M | $1M | $2M | $2M | $1M |
| Total assets | $16M | $307M | $266M | $226M | $364M | $283M |
| Total current liabilities | $2M | $4M | $6M | $15M | $15M | $18M |
| Total liabilities | $2M | $5M | $8M | $22M | $20M | $23M |
| Shareholders' equity | -$14M | $302M | $258M | $204M | $343M | $259M |
| Net debt | -$15M | -$302M | -$251M | -$58M | -$92M | -$77M |
Cash flow
Fiscal years, from Tyra Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8M | -$24M | -$50M | -$50M | -$70M | -$95M |
| Capital spending | $312,000 | $661,000 | $559,000 | $770,000 | $664,000 | $141,000 |
| Free cash flow | -$8M | -$24M | -$51M | -$51M | -$70M | -$95M |
| Stock-based compensation | $439,000 | $3M | $11M | $14M | $23M | $28M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TYRA.
Open TYRA in InvestinglyQuestions
How much free cash flow does Tyra Biosciences generate?
-$95M in fiscal 2025 (operating cash flow minus capital spending).
From Tyra Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.